Odyssey Health Inc.

Odyssey Health Inc.

OOTC:ODYY
0.01
USD
0.00
(0.00%)
-0.05EPS
762,974.37Market Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
-0.34
-0.05
-0.18
-0.09
-0.07
-0.01
- -
-0.05
-0.05
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
-0.01
-0.04
-0.04
-0.02
-0.01
- -
-0.01
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.03
-0.06
-0.08
-0.06
- -
-0.11
-0.11
Tangible Book Value per Share
- -
- -
- -
-0.01
-0.01
-0.01
-0.03
-0.06
-0.08
-0.06
- -
-0.11
-0.11
Basic Weighted Avg Shares
115
115
115
117
70
87
94
89
83
97
105
108
107
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-60.61
-196.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
-23
-4
-17
-8
-6
-1
- -
-6
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-62.47
-229.94
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
-1
-1
-1
-1
-3
-5
-6
-6
- -
-12
-12
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
-1
-1
-1
-3
-5
-6
-5
- -
-12
-12
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Jan'26
Apr'26
Jul'26
ST Debt
2
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
101
106
Market Capitalization
7
6
1

Working Capital

USD

•

in mil. unless spec.
Jan'26
Apr'26
Jul'26
Total Current Assets
1
- -
- -
Cash, Cash Equivalents & STI
1
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
11
10
12
Payables & Accruals
4
4
3
ST Debt
2
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.01
0.14
-0.01
-0.13
-0.01
2025
-0.01
- -
- -
- -
- -
2026
- -
-0.03
0.01
-0.02
-0.05

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Joseph Michael Redmond
Full Time Employees
2
Sector
Health technology
Industry
Medical specialties
Address
2300 West Sahara Avenue Las Vegas NV United States 89102
IPO Date
Jan 13, 2017
Business
Odyssey Health, Inc. operates as a medical technology enterprise, concentrating on the advancement of distinctive health solutions. The company is actively developing CardioMap, a non-invasive monitoring and screening device for cardiac health, alongside the Save A Life choking rescue mechanism. Through its subsidiary, Odyssey recently acquired exclusive worldwide sub-licensing rights for BreastCheck®, an innovative at-home screening test for breast abnormalities. Headquartered in Las Vegas, Nevada, the firm, previously known as Odyssey Group International, Inc., commenced operations in 2014.

Company News

  • Odyssey Health, Inc. (OTCMKTS:ODYY) Sees Significant Decline in Short Interest

  • Head-To-Head Review: Odyssey Health (OTCMKTS:ODYY) & Enovis (NYSE:ENOV)

  • Odyssey Health, Inc. Secures Exclusive Global Distribution Rights for BreastCheck™ to Drive Recurring Revenue Growth

  • Odyssey Health, Inc. (OTCMKTS:ODYY) Short Interest Update

  • Odyssey Health, Inc. Secures Multi-Million-Dollar, Nine-Year Service Contract and Financing Facility for Up to $25 Million

  • Odyssey Health, Inc., Enters the $26 Billion Breast Cancer Marketplace

  • Odyssey Health, Inc. to Advance Development of its Save A Life Choking Rescue Device

  • Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity

  • Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.

  • Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.

  • Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion

  • Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders

  • Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.

  • Odyssey Health Inc. Begins Trading on the OTCQB

  • Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device

  • Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion

  • Odyssey Group International Approved to Start Human Trial to Treat Concussion

  • Odyssey Group International Completes IND-enabling Studies, Submits Investigator's Brochure for Phase 1 Clinical Trial

  • Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders

  • Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion